logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Metastatic Colorectal Carcinoma

    Medications for Metastatic Colorectal Carcinoma

    FiltersReset Filters
    5 results

    • avastin

      (bevacizumab)
      Genentech, Inc.
      Usage: Avastin is indicated for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent or recurrent cervical cancer, and advanced epithelial ovarian or peritoneal cancers, often in combination with other chemotherapy agents.

    • braftovi

      (Encorafenib)
      Array BioPharma Inc.
      Usage: BRAFTOVI is indicated for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer, all positive for BRAF V600E or V600K mutations. These treatments require combination therapies and FDA-approved testing for mutation detection. Not for wild-type BRAF cancers.

    • vectibix

      (panitumumab)
      Amgen Inc
      Usage: Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as first-line therapy with FOLFOX or as monotherapy after prior chemotherapy. It is also approved for KRAS G12C-mutated mCRC in combination with sotorasib in previously treated patients.

    • zaltrap

      (ziv-aflibercept)
      sanofi-aventis U.S. LLC
      Usage: ZALTRAP, combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after treatment with an oxaliplatin-containing regimen.

    • zirabev

      (bevacizumab-bvzr)
      Pfizer Laboratories Div Pfizer Inc
      Usage: ZIRABEV is indicated for treating metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent/recurrent/metastatic cervical cancer, and advanced epithelial ovarian/fallopian tube/peritoneal cancer, often in combination with other chemotherapy agents.